Development of novel medication strategy and drug efficacy on monocyte lineage cells of a JAK3 inhibitor in rheumatoid arthritis patients

点击翻译按钮获取中文摘要

In order to evaluate the effect of a Jak3-inhibitor CP690, 550(CP) on rheumatoid arthritis patients, we have focused on monocyte lineage cells, a progenitor for osteoclasts essential for bone resorption and dendritic cells(DCs) that functions as a start point of immune reaction. Differentiation of osteoclasts and DCs were not affected by the addition of CP. Bone resorption of osteoclasts was not affected by CP as well. Although, expression of co-stimulatory molecules on DCs were suppressed and co-culture of lymphocytes resulted in suppressed lymphocyte proliferation and IFN-g production.